Literature DB >> 20567869

Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia.

S Padrones1, C Garcia-Vidal, S Fernández-Serrano, A Fernández, C Masuet, J Carratalà, M Coromines, C Ardanuy, F Gudiol, F Manresa, J Dorca.   

Abstract

The aim of this study was to compare the evolution of systemic cytokine levels over time in patients with pneumococal pneumonia treated either with β-lactam monotherapy or with combination therapy (β-lactam plus fluoroquinolone). Prospective observational study of hospitalized non-immunocompromised adults with PP. Concentrations of IL-6, IL-8, IL-10, and TNF-α were determined on days 0, 1, 2, 3, 5, and 7. Patients on β-lactam monotherapy were compared with those receiving combination therapy. Fifty-two patients were enrolled in the study. Concentrations of IL-6, IL-8, and IL-10 decreased rapidly in the first days after admission, in accordance with the mean time to defervescence. High levels of IL-6 were found in patients with the worst outcomes, measured by the need for intensive care unit admission and mortality. No major differences in demographic or clinical characteristics or severity of disease were found between patients treated with β-lactam monotherapy and those treated with combination therapy. IL-6 levels fell more rapidly in patients with combination therapy in the first 48 h (p = 0.016). Our data suggest that systemic expression of IL-6 production in patients with PP correlates with prognosis. Initial combination antibiotic therapy produces a faster decrease in this cytokine in the first 48 h.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20567869     DOI: 10.1007/s10096-010-0993-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  29 in total

1.  Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.

Authors:  José A Martínez; Juan P Horcajada; Manuel Almela; Francesc Marco; Alex Soriano; Elisa García; Maria Angeles Marco; Antoni Torres; Josep Mensa
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079

2.  PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA.

Authors:  R AUSTRIAN; J GOLD
Journal:  Ann Intern Med       Date:  1964-05       Impact factor: 25.391

3.  Systemic cytokine levels in community-acquired pneumonia and their association with disease severity.

Authors:  G Antunes; S A Evans; J L Lordan; A J Frew
Journal:  Eur Respir J       Date:  2002-10       Impact factor: 16.671

Review 4.  Immunomodulating effects of antibiotics: literature review.

Authors:  B Van Vlem; R Vanholder; P De Paepe; D Vogelaers; S Ringoir
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

5.  Cytokine expression in severe pneumonia: a bronchoalveolar lavage study.

Authors:  C Montón; A Torres; M El-Ebiary; X Filella; A Xaubet; J P de la Bellacasa
Journal:  Crit Care Med       Date:  1999-09       Impact factor: 7.598

6.  Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents. The role of cAMP-mediated signaling mechanisms.

Authors:  T A Blaine; P F Pollice; R N Rosier; P R Reynolds; J E Puzas; R J O'Keefe
Journal:  J Bone Joint Surg Am       Date:  1997-10       Impact factor: 5.284

7.  Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.

Authors:  G W Waterer; G W Somes; R G Wunderink
Journal:  Arch Intern Med       Date:  2001 Aug 13-27

Review 8.  Immunomodulatory effects of quinolones.

Authors:  Axel Dalhoff; Itamar Shalit
Journal:  Lancet Infect Dis       Date:  2003-06       Impact factor: 25.071

9.  Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone.

Authors:  Esther Calbo; Montserrat Alsina; Mónica Rodríguez-Carballeira; Josep Lite; Javier Garau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

10.  Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells.

Authors:  Jung-Hyun Choi; Min-Jin Song; Seung-Han Kim; Su-Mi Choi; Dong-Gun Lee; Jin-Hong Yoo; Wan-Shik Shin
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

View more
  4 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial.

Authors:  Silvia Fernández-Serrano; Jordi Dorca; Carolina Garcia-Vidal; Núria Fernández-Sabé; Jordi Carratalà; Ana Fernández-Agüera; Mercè Corominas; Susana Padrones; Francesc Gudiol; Frederic Manresa
Journal:  Crit Care       Date:  2011-03-15       Impact factor: 9.097

3.  Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia.

Authors:  Rosario Menéndez; José Miguel Sahuquillo-Arce; Soledad Reyes; Raquel Martínez; Eva Polverino; Catia Cillóniz; Juan Ginés Córdoba; Beatriz Montull; Antoni Torres
Journal:  Chest       Date:  2011-12-22       Impact factor: 9.410

4.  HDL-c levels predict the presence of pleural effusion and the clinical outcome of community-acquired pneumonia.

Authors:  M Saballs; S Parra; P Sahun; J Pellejà; M Feliu; C Vasco; J Gumà; J L Borràs; L Masana; A Castro
Journal:  Springerplus       Date:  2016-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.